Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Research Paper
Open Access

Reduced signal propagation elicited by frontal transcranial magnetic stimulation is associated with oligodendrocyte abnormalities in treatment-resistant depression

Masataka Wada, Shinichiro Nakajima, Shiori Honda, Mayuko Takano, Keita Taniguchi, Sakiko Tsugawa, Yu Mimura, Nanao Hattori, Shinsuke Koike, Reza Zomorrodi, Daniel M. Blumberger, Zafiris J. Daskalakis, Masaru Mimura and Yoshihiro Noda
J Psychiatry Neurosci September 14, 2022 47 (5) E325-E335; DOI: https://doi.org/10.1503/jpn.220102
Masataka Wada
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinichiro Nakajima
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shiori Honda
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayuko Takano
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keita Taniguchi
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sakiko Tsugawa
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Mimura
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nanao Hattori
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinsuke Koike
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reza Zomorrodi
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel M. Blumberger
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zafiris J. Daskalakis
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Mimura
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihiro Noda
From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Wada, Nakajima, Honda, Takano, Taniguchi, Tsugawa, Y. Mimura, Hattori, M. Mimura, Noda); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Nakajima); Teijin Pharma Ltd., Tokyo, Japan (Takano); the Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, University of Tokyo, Tokyo, Japan (Koike); the Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont. (Zomorrodi, Blumberger); the Department of Psychiatry, Faculty of Health, University of California San Diego, San Diego, CA (Daskalakis)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Fig. 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1

    Schematic diagram showing how combined TMS-EEG and MRI data were used to assess signal propagation in this study. (A) Brain neural activities comprise 3 main categories: noncausal correlated activity in the resting state; neural activity elicited by a specific task, which is assessed with endogenous neural activity specific to the task modality, elicited in the specific neural module corresponding to the task; and causal neural activity with a clear input–output relationship using an external mechanical physical stimulus as a probe. The first 2 categories have a limitation: although they can be used to evaluate local activity as the sum of the interactions between regions in the entire brain, they cannot be used to evaluate activity in the local brain region itself. The third category (extrinsic neural stimulation targeting specific brain regions using TMS as a probe) is characterized by its ability to evaluate both neural activity at the stimulation site and neural activity originating from the stimulation site to other regions to determine causal relationships, independent of neural activity from regions other than the stimulation site. (B) Rationale for using TMS-EEG to assess signal propagation in the present study. TMS-evoked neural activities (within and between regions) that show significant signal propagation from the stimulation site to other specific brain regions or neural networks are propagated in a causal manner. (C) An overview of TMS-EEG data analysis. First, for reconstruction of the TEP signal source, we manually registered EEG channel locations on individual MRI spaces, along with anatomic landmarks. Then, we projected EEG source activations onto individual surface spaces using forward and inverse modelling of EEG sources. Finally, to compare signal propagation from the stimulation site to each brain network between the TRD and healthy control groups, we extracted dSPM current densities from the 7 networks defined by Yeo and colleagues.31 To investigate the cellular-level abnormalities that would be associated with the signal propagation abnormalities, we examined correlations between the interregional profiles of cell-specific gene expression using the Allen Human Brain Atlas data set and the interregional profiles of altered signal propagation from our TMS-EEG data. dlPFC = dorsolateral prefrontal cortex; dSPM = dynamic statistical parametric mapping; EEG = electroencephalography; HC = healthy control; ROI = region of interest; TEP = TMS-evoked potential; TMS = transcranial magnetic stimulation; TRD = treatment-resistant depression.

  • Fig. 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2

    Butterfly plots of the TEP waveforms among healthy controls (top) and patients with TRD (bottom). The TMS post-stimulus interval (−5 to 30 ms) is shown as a grey bar because of data cut-offs. Topoplots corresponding to the N100 and P180 components of the TEP are shown alongside the butterfly plots for both groups. In the butterfly plots, the colour of each waveform corresponds to the electrode colour diagram in the upper left corner, and the yellow symbols indicate TMS stimulation sites. TEP = TMS-evoked potential; TMS = transcranial magnetic stimulation; TRD = treatment-resistant depression.

  • Fig. 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3

    Time–frequency analyses with ERSP. (A) ERSP from all electrode sites. (B) ERSP from electrodes corresponding to the stimulation site (i.e., left dlPFC). The ERSPs elicited by single-pulse TMS are shown for healthy controls in the upper left, and for patients with TRD in the upper right. Differences between the 2 groups are shown in the lower left. Areas with no significant differences between groups on the 2-dimensional cluster-level permutation tests are shown by green masks in the lower right. In each condition, the ERSPs for patients with TRD were significantly lowered in the θ band compared to healthy controls (all electrodes: p = 0.019, uncorrected; stimulation site (left dlPFC): p = 0.017, uncorrected; α = 0.05). dlPFC = dorsolateral prefrontal cortex; ERSP = event-related spectral perturbation; HC = healthy control; TMS = transcranial magnetic stimulation; TRD = treatment-resistant depression.

  • Fig. 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4

    Source-based time–frequency analyses with evoked power in the salience network. Evoked power is shown for healthy controls in the upper left, and for patients with TRD in the upper right. Differences in evoked power between the 2 groups are shown in the lower left. Areas with no significant differences between groups on the 2-dimensional cluster-level permutation tests are shown by green masks in the lower right. Evoked power in patients with TRD was significantly lower than in healthy controls (p = 0.005, uncorrected; α = 0.007). HC = healthy control; TRD = treatment-resistant depression.

  • Fig. 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5

    Mean correlation coefficients for the degree of gene expression and altered TMS-EEG signal propagation in corresponding inter-regional profiles. We evaluated the significance of the average interregional correlations between gene expression and altered signal propagation for each cell type, compared to an empirical null distribution of correlation coefficients between the expression profiles of random gene sets and the signal propagation profile. The black line indicates the estimated probability density function for the correlation coefficients between each cell-type gene expression level and the signal propagation profiles from our data. The lower and upper cut-off for significance is indicated by the vertical edges of the shaded grey box. The mean correlation coefficients for each cell type are indicated by dashed red lines. The following cell types differed significantly from the empirical null distributions, even after correcting for multiple comparisons (p values uncorrected): oligodendrocytes (p < 0.000001; α = 0.0056); CA1 pyramidal neurons (p < 0.000001; α = 0.0056); S1 pyramidal neurons (p = 0.00003; α = 0.0056); and interneurons (p < 0.000001; α = 0.0056). CA1 = cornu ammonis 1; TMS = transcranial magnetic stimulation; S1 = somatosensory cortex.

Tables

  • Figures
    • View popup
    Table 1

    Participant demographics

    Characteristic*Patients with TRD
    n = 60
    Healthy controls
    n = 30
    Statistics†
    Age, yr45.37 ± 11.8545.63 ± 13.16t88 = 0.096, p = 0.92
    Female, %4040χ288 = 0.0, p = 1.0
    Education, yr15.3 ± 1.914.7 ± 2.1t88 = 1.50, p = 0.14
    MMSE score29.1 ± 1.428.5 ± 3.3t88 = 1.38, p = 0.17
    Age at onset of TRD, yr36.0 ± 15.6——
    Duration of illness, yr10.9 ± 9.2——
    MADRS score32.1 ± 7.1——
    • MADRS = Montgomery–Åsberg Depression Rating Scale; MMSE = Mini-Mental State Examination; TRD = treatment-resistant depression.

    • ↵* Values are mean ± standard deviation or %.

    • ↵† p values are uncorrected.

PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 47 (5)
J Psychiatry Neurosci
Vol. 47, Issue 5
25 Oct 2022
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reduced signal propagation elicited by frontal transcranial magnetic stimulation is associated with oligodendrocyte abnormalities in treatment-resistant depression
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Reduced signal propagation elicited by frontal transcranial magnetic stimulation is associated with oligodendrocyte abnormalities in treatment-resistant depression
Masataka Wada, Shinichiro Nakajima, Shiori Honda, Mayuko Takano, Keita Taniguchi, Sakiko Tsugawa, Yu Mimura, Nanao Hattori, Shinsuke Koike, Reza Zomorrodi, Daniel M. Blumberger, Zafiris J. Daskalakis, Masaru Mimura, Yoshihiro Noda
J Psychiatry Neurosci Sep 2022, 47 (5) E325-E335; DOI: 10.1503/jpn.220102

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Reduced signal propagation elicited by frontal transcranial magnetic stimulation is associated with oligodendrocyte abnormalities in treatment-resistant depression
Masataka Wada, Shinichiro Nakajima, Shiori Honda, Mayuko Takano, Keita Taniguchi, Sakiko Tsugawa, Yu Mimura, Nanao Hattori, Shinsuke Koike, Reza Zomorrodi, Daniel M. Blumberger, Zafiris J. Daskalakis, Masaru Mimura, Yoshihiro Noda
J Psychiatry Neurosci Sep 2022, 47 (5) E325-E335; DOI: 10.1503/jpn.220102
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire